<DOC>
	<DOC>NCT02148185</DOC>
	<brief_summary>The purpose of this study is to evaluate PK, PD and safety of a single oral dose of MT-1303 in subjects with Crohn's disease.</brief_summary>
	<brief_title>Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease</brief_title>
	<detailed_description>This is a Phase I, open-label, non-randomised, multicenter single-dose study to evaluate PK, PD, and safety of a single oral dose of MT-1303 in subjects with moderate to severe active Crohn's disease (ileal and ileo-colonic type).</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects who were diagnosed as Crohn's disease Subjects who were confirmed as ileal or ileocolonic type by image inspection. Disease severity determined as either "moderate" or "severe" Present or past history of gastrointestinal surgery which may have impact on drug absorption Subjects with stenosis or fistula in small intestine or colon</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Crohn's disease</keyword>
</DOC>